Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RH5.2 VLP and R21 Malaria Vaccines in Adults and Infants in the Gambia
NCT05357560Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of RH5.2 virus-like particle and R21/Matrix-M in malaria (9 arms), sponsored by University of Oxford. Primary endpoints: Occurrence of solicited local reactogenicity signs and symptoms, Occurrence of solicited systemic reactogenicity signs and symptoms and 3 more. Started Jul 2023; status: completed.
02
Drugs
RH5.2 virus-like particleR21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05357560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357560.